Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Phio Pharmaceuticals Corp (PHIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PHIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -35.04% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.28M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 0.85 | 52 Weeks Range 0.97 - 9.79 | Updated Date 07/1/2025 |
52 Weeks Range 0.97 - 9.79 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.43% | Return on Equity (TTM) -76.12% |
Valuation
Trailing PE - | Forward PE 0.31 | Enterprise Value 2820661 | Price to Sales(TTM) 48.01 |
Enterprise Value 2820661 | Price to Sales(TTM) 48.01 | ||
Enterprise Value to Revenue 172.2 | Enterprise Value to EBITDA 0.61 | Shares Outstanding 4798150 | Shares Floating 4779153 |
Shares Outstanding 4798150 | Shares Floating 4779153 | ||
Percent Insiders 0.4 | Percent Institutions 15.77 |
Analyst Ratings
Rating 1 | Target Price 14 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Phio Pharmaceuticals Corp
Company Overview
History and Background
Phio Pharmaceuticals Corp., (PHIO) formerly RXi Pharmaceuticals, was founded in 2011. The company focuses on developing self-delivering RNAi therapeutics to treat diseases. It leverages its INTASYL platform to design and develop compounds that silence disease-causing genes.
Core Business Areas
- RNAi Therapeutics Development: Phio focuses on research and development of RNAi-based therapeutics to target specific genes involved in disease pathways.
- INTASYL Platform: Phio's proprietary INTASYL technology platform enables the development of self-delivering RNAi therapeutics.
Leadership and Structure
James P. Caruso is the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- INTASYL-based RNAi therapeutics: Phio's primary focus is on developing RNAi therapeutics using its INTASYL platform. Currently, they are in preclinical and clinical stages. Specific market share data is unavailable, since no product has been commercialized. Competitors include Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), and Dicerna Pharmaceuticals (acquired by Novo Nordisk).
Market Dynamics
Industry Overview
The RNAi therapeutics market is growing, driven by advancements in delivery technologies and the potential to target previously undruggable genes. The field is highly competitive, with several companies pursuing different approaches to RNAi delivery and target selection.
Positioning
Phio is positioned as a company specializing in self-delivering RNAi therapeutics. Their INTASYL platform is a key differentiator. However, they are smaller compared to larger players like Alnylam and Arrowhead.
Total Addressable Market (TAM)
The global RNA therapeutics market is expected to reach $2.1 billion in 2024 and grow to $4.3 billion by 2029. Phio is trying to carve out a niche within this large market. The company focuses on novel approaches, but its relatively small size impacts its ability to penetrate the overall RNAi therapeutics TAM.
Upturn SWOT Analysis
Strengths
- Proprietary INTASYL technology platform
- Focus on self-delivering RNAi therapeutics
- Experienced leadership team
- Targeting of specific genes for disease treatment
Weaknesses
- Limited financial resources
- Reliance on early-stage pipeline
- No currently marketed products
- Susceptible to clinical trial failures
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of INTASYL platform to new therapeutic areas
- Advancements in RNAi delivery technologies
- Regulatory approvals for RNAi therapeutics
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Patent challenges
- Funding constraints
- Evolving regulatory landscape
Competitors and Market Share
Key Competitors
- ALNY
- ARWR
- SNY
Competitive Landscape
Phio faces significant competition from established players in the RNAi therapeutics market. Its smaller size and limited resources present challenges in competing with larger companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development. The company's value is tied to its pipeline progress.
Future Projections: Future projections are highly speculative and dependent on successful clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing their pipeline of RNAi therapeutics and seeking partnerships for development and commercialization.
Summary
Phio Pharmaceuticals is a developmental-stage company focused on RNAi therapeutics using its INTASYL platform. Its success depends on clinical trial progress and securing partnerships. The company faces significant competition and funding challenges. Successful clinical trials and strategic collaborations are critical for future growth. Investors should monitor clinical trial data closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Third-party financial data providers
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phio Pharmaceuticals Corp
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 2012-05-10 | President, CEO & Chairman Mr. Robert J. Bitterman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://phiopharma.com |
Full time employees 5 | Website https://phiopharma.com | ||
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.